Eisai: We were cheated on Belviq, Fycompa NCE exclusivity
This article was originally published in Scrip
Executive Summary
Eisai said the FDA has cheated the firm out of its full five years of marketing exclusivity protection Congress intended for the company's anti-obesity drug Belviq (lorcaserin) and its anti-seizure medicine Fycompa (perampanel), which were deemed new chemical entities (NCEs) – with the manufacturer insisting US regulators started the clock too soon on the products.